Abby Hardy, Author at BioTuesdays

Developments

Ocutrx Vision receives second patent for augmented reality glasses eye tracking technology

Closely-held Ocutrx Vision Technologies announced issuance of the company’s second U.S. patent, which will protect the company’s unique eye tracking technology for patients with macular degeneration and other low vision...

April 2, 2019

Developments

Aphria launches CBD-based products in Germany

Aphria (TSX:APHA; NYSE:APHA) has launched CannRelief, a cannabidiol (CBD)-based nutraceutical and cosmetics line, through its subsidiary Aphria Deutschland. Featuring hemp-derived CBD, CannRelief products are produced...

April 1, 2019

Developments

CHMP affirms omega-3s do not prevent further problems after heart attack

The European Medicine Agency’s (EMA) advisory committee (CHMP) affirmed that a 1gm daily dose of omega-3s are not effective in preventing further cardiovascular (CV) problems in patients who have had a heart attack. The...

March 29, 2019

Markets

Maxim cuts Proteon Therapeutics to hold; removes PT

Maxim Group downgraded Proteon Therapeutics (NASDAQ:PRTO) to “hold” from “buy” and withdrew its previous $5 price target after the company’s second Phase 3 study of vonapanitase failed to reach statistical significance...

March 28, 2019

Executive Moves

Roth promotes Yasmeen Rahimi to co-head biotech research

Roth Capital Partners promoted Yasmeen Rahimi, managing director and senior research analyst, to the position of co-head of biotechnology research.

March 28, 2019

Developments

Lutronic Vision retains retina expert to lead R:GEN pilot AMD clinical study

Closely-held Lutronic Vision retained professor Robyn Guymer, a world-renowned age-related macular degeneration (AMD) expert and key opinion leader, to serve as the principal investigator for its planned pilot clinical...

March 27, 2019

Developments

Altimmune’s NasoVAX provides 100% seroprotection more than one year after vaccination

Altimmune’s (NASDAQ:ALT) intranasal influenza vaccine, NasoVAX, demonstrated a seroprotective antibody response in all subjects who received the vaccine more than one year ago. The Phase 2a trial of NasoVAX was...

March 20, 2019

Developments

GeoVax study suggests Ebola vaccine could provide 100% protection with single dose

GeoVax Labs (OTCQB:GOVX) published research showing that a single intramuscular dose of its Ebola vaccine, GEO-EM01, provided 100% protection in rhesus macaques challenged with a lethal dose of Ebola virus. GEO-EM01...

March 20, 2019

Developments

Dermira atopic dermatitis drug meets primary endpoint in Phase 2b study

Dermira’s (NASDAQ:DERM) Phase 2b dose-ranging study of lebrikizumab in atopic dermatitis demonstrated that all three doses achieved greater improvements in the Eczema Area and Severity Index score, compared with placebo...

March 19, 2019

Developments

Moleculin Biotech treats first patients in Phase 1/2 Annamycin trial, requests fast track designation

Moleculin Biotech (NASDAQ:MBRX) has treated the first patients in its European Phase 1/2 clinical trial of Annamycin for relapsed and refractory acute myeloid leukemia (AML). The company also submitted a request to the...

March 14, 2019

Author - Abby Hardy

Ocutrx Vision receives second patent for augmented reality glasses eye tracking technology

Aphria launches CBD-based products in Germany

CHMP affirms omega-3s do not prevent further problems after heart attack

Maxim cuts Proteon Therapeutics to hold; removes PT

Roth promotes Yasmeen Rahimi to co-head biotech research

Lutronic Vision retains retina expert to lead R:GEN pilot AMD clinical study

Altimmune’s NasoVAX provides 100% seroprotection more than one year after vaccination

GeoVax study suggests Ebola vaccine could provide 100% protection with single dose

Dermira atopic dermatitis drug meets primary endpoint in Phase 2b study

Moleculin Biotech treats first patients in Phase 1/2 Annamycin trial, requests fast track designation

Subscribe